{"ticker": {"uuid": "94f6d8a8-5841-4948-951d-f63d0f95de95", "symbol": "HRMY", "name": "Harmony Biosciences Holdings", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge", "summary": "BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over year to $243.7 million, beating the Zacks Consensus Estimate of $222.6 million. This growth was primarily driven by its sole marketed drug, Attruby. Year to date, BridgeBio's shares have gained 11% compared with the industry's 7% growth.Zacks Investment Research Image Source: Zacks Investment Research BBIO's Attruby Sales Drive the Top Line A", "url": "https://finance.yahoo.com/healthcare/articles/bridgebio-q2-earnings-miss-revenues-164500986.html", "source_link": "https://finance.yahoo.com/healthcare/articles/bridgebio-q2-earnings-miss-revenues-164500986.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:45:00+00:00", "published_display": "11 Aug 2026 16:45", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Beat expectations", "Improving financial comparison", "Deteriorating financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176759, "evidence_share": 19.0, "evidence_share_display": "19", "freshness_pct": 76.2, "age_days": 2.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "EARNINGS PER SHARE"], "evidence_basis": "", "score_included": true}, {"title": "ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut", "summary": "ANI Pharmaceuticals ANIP reported second-quarter 2026 adjusted EPS of $2.21, beating the Zacks Consensus Estimate of $2.01. The reported figure rose 23% year over year, driven by higher sales during the quarter. Quarterly revenues totaled $266 million, up 26% from the year-ago period. The metric also beat the Zacks Consensus Estimate of $262.7 million. The quarter reflected solid execution across the portfolio, led by continued momentum for Purified Cortrophin Gel and contributions from a newly monetized intellectual property licensing arrangement. ANI's Rare Disease Business Shows Mixed Trend", "url": "https://finance.yahoo.com/healthcare/articles/anip-tops-q2-earnings-stock-170500106.html", "source_link": "https://finance.yahoo.com/healthcare/articles/anip-tops-q2-earnings-stock-170500106.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:05:00+00:00", "published_display": "10 Aug 2026 17:05", "source_kind": "aggregator", "sentiment": "negative", "sentiment_pct": 39, "tone_signals": ["Guidance cut", "Beat expectations", "Missed expectations", "Improving financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.121961, "evidence_share": 13.1, "evidence_share_display": "13.1", "freshness_pct": 66.4, "age_days": 2.9, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "EARNINGS", "Earnings", "FOURTH QUARTER", "Fourth Quarter"], "evidence_basis": "", "score_included": true}, {"title": "OTLK Up More Than 300% in 3 Months: Here's What You Should Know", "summary": "Shares of Outlook Therapeutics OTLK have witnessed a significant surge over the past three months, primarily driven by growing investor optimism related to the company's sole product, Lytenava, which is approved for the treatment of patients with wet age-related macular degeneration (wet AMD). OTLK's Price Performance Shares of Outlook Therapeutics have skyrocketed 311.8% in the past three months compared with the industry's increase of 6.9%.Zacks Investment Research Image Source: Zacks Investment Research Last month, the FDA approved Lytenava for the treatment of neovascular age-related macul", "url": "https://finance.yahoo.com/healthcare/articles/otlk-more-300-3-months-152700954.html", "source_link": "https://finance.yahoo.com/healthcare/articles/otlk-more-300-3-months-152700954.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:27:00+00:00", "published_display": "10 Aug 2026 15:27", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 80, "tone_signals": ["Beat expectations", "Missed expectations", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.183536, "evidence_share": 19.7, "evidence_share_display": "19.7", "freshness_pct": 65.8, "age_days": 3.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share"], "evidence_basis": "", "score_included": true}, {"title": "Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months", "summary": "Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader pipeline. The rally has been driven primarily by a series of positive regulatory developments that substantially reduced uncertainty surrounding RP1's path to commercialization. FDA Approves REPL's RP1 for Advanced Melanoma Earlier this month, the FDA granted accelerated approval to RP1 (vusolimogene oderparepvec) under the brand name Tudriqev, in combination", "url": "https://finance.yahoo.com/healthcare/articles/heres-why-replimune-stock-skyrockets-141700559.html", "source_link": "https://finance.yahoo.com/healthcare/articles/heres-why-replimune-stock-skyrockets-141700559.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:17:00+00:00", "published_display": "10 Aug 2026 14:17", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 84, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.239233, "evidence_share": 25.7, "evidence_share_display": "25.7", "freshness_pct": 73.8, "age_days": 3.1, "influence_label": "High", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share"], "evidence_basis": "", "score_included": true}, {"title": "Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline Progress - What's Changed", "summary": "Harmony Biosciences Holdings, Inc. recently reported second-quarter 2026 results showing net income of US$75.43 million, up from US$39.78 million a year earlier, with basic earnings per share from continuing operations rising to US$1.30 from US$0.69. Alongside these stronger earnings, the company reported progress across its neurology pipeline and clinical trials for rare neurological diseases, which could influence how investors view the balance between its current cash-generating products and longer-term development assets. We'll now examine how Harmony's sharp year-over-year earnings improv", "url": "https://finance.yahoo.com/healthcare/articles/harmony-biosciences-hrmy-9-0-231334275.html", "source_link": "https://finance.yahoo.com/healthcare/articles/harmony-biosciences-hrmy-9-0-231334275.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T23:13:34+00:00", "published_display": "07 Aug 2026 23:13", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 74, "tone_signals": ["Improving financial comparison", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.13031, "evidence_share": 14.0, "evidence_share_display": "14", "freshness_pct": 45.4, "age_days": 5.7, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "EARNINGS PER SHARE"], "evidence_basis": "", "score_included": true}, {"title": "Harmony Biosciences (HRMY) Stock Jumps On Profit Surge As Margin Pressure Lingers", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Harmony+Biosciences+%28HRMY%29+Stock+Jumps+On+Profit+Surge+As+Margin+Pressure+Lingers%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-08-05T07:45:25.721250+00:00", "published_display": "05 Aug 2026 07:45", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Margin pressure", "Operating growth", "Positive market reaction"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.03609, "evidence_share": 3.9, "evidence_share_display": "3.9", "freshness_pct": 31.5, "age_days": 8.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Harmony+Biosciences+%28HRMY%29+Stock+Looks+Below+Fair+Value+On+Earnings%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-08-02T08:09:52.665582+00:00", "published_display": "02 Aug 2026 08:09", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.014985, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 20.8, "age_days": 11.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "HRMY Maintained by Mizuho -- Price Target Raised to $51.00", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22HRMY+Maintained+by+Mizuho+--+Price+Target+Raised+to+%2451.00%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-08-01T10:25:37.513979+00:00", "published_display": "01 Aug 2026 10:25", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Analyst upgrade"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006331, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 5.9, "age_days": 12.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Should Value Investors Buy Harmony Biosciences (HRMY) Stock?", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Should+Value+Investors+Buy+Harmony+Biosciences+%28HRMY%29+Stock%3F%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-07-31T00:16:36.107826+00:00", "published_display": "31 Jul 2026 00:16", "source_kind": "aggregator", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000378, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.9, "age_days": 13.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative?", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Did+CFO+Exit+and+Reaffirmed+2026+Guidance+Just+Shift+Harmony+Biosciences%27+%28HRMY%29+Investment+Narrative%3F%22+%22Simply+Wall+Street%22", "source_link_is_lookup": true, "source_name": "Simply Wall Street", "published_at": "2026-07-27T02:14:24.559950+00:00", "published_display": "27 Jul 2026 02:14", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.015168, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 17.6, "age_days": 17.6, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Is Harmony Biosciences' Growth Story Still Compelling in 2026", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Is+Harmony+Biosciences%27+Growth+Story+Still+Compelling+in+2026%22+%22Kavout+%7C+AI%22", "source_link_is_lookup": true, "source_name": "Kavout | AI", "published_at": "2026-07-25T06:21:53.666620+00:00", "published_display": "25 Jul 2026 06:21", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5.6e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 19.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "H.C. Wainwright reiterates Harmony Biosciences stock rating on demand beat", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22H.C.+Wainwright+reiterates+Harmony+Biosciences+stock+rating+on+demand+beat%22+%22Investing.com%22", "source_link_is_lookup": true, "source_name": "Investing.com", "published_at": "2026-07-21T00:38:18.298961+00:00", "published_display": "21 Jul 2026 00:38", "source_kind": "publisher", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000402, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.4, "age_days": 23.6, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Harmony Biosciences Holdings (HRMY) Is Down 8.3% After Reaffirming 2026 Guidance And CFO Transition - Has The Bull Case Changed?", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Harmony+Biosciences+Holdings+%28HRMY%29+Is+Down+8.3%25+After+Reaffirming+2026+Guidance+And+CFO+Transition+-+Has+The+Bull+Case+Changed%3F%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-07-18T17:19:35.386073+00:00", "published_display": "18 Jul 2026 17:19", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006621, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 7.7, "age_days": 25.9, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22HRMY+Posts+Preliminary+Q2+Revenues%2C+Announces+CFO+Transition%22+%22TradingView%22", "source_link_is_lookup": true, "source_name": "TradingView", "published_at": "2026-07-18T15:49:04.642231+00:00", "published_display": "18 Jul 2026 15:49", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 26.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Zacks.com featured highlights Harmony, StoneCo, General Motors, Hewlett and Nexa", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Zacks.com+featured+highlights+Harmony%2C+StoneCo%2C+General+Motors%2C+Hewlett+and+Nexa%22+%22Zacks%22", "source_link_is_lookup": true, "source_name": "Zacks", "published_at": "2026-07-15T12:26:09.999831+00:00", "published_display": "15 Jul 2026 12:26", "source_kind": "publisher", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 29.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "by_tier": {"direct": [{"title": "BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge", "summary": "BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over year to $243.7 million, beating the Zacks Consensus Estimate of $222.6 million. This growth was primarily driven by its sole marketed drug, Attruby. Year to date, BridgeBio's shares have gained 11% compared with the industry's 7% growth.Zacks Investment Research Image Source: Zacks Investment Research BBIO's Attruby Sales Drive the Top Line A", "url": "https://finance.yahoo.com/healthcare/articles/bridgebio-q2-earnings-miss-revenues-164500986.html", "source_link": "https://finance.yahoo.com/healthcare/articles/bridgebio-q2-earnings-miss-revenues-164500986.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:45:00+00:00", "published_display": "11 Aug 2026 16:45", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "f61f3c578f57f6e201b10f2d4796ecfcd3abda2742be3399f748b9c3b925c8e5", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.738, "provider_directional_mass": 0.1389, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.527, "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Beat expectations", "Improving financial comparison", "Deteriorating financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176759, "evidence_share": 19.0, "evidence_share_display": "19", "freshness_pct": 76.2, "age_days": 2.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "EARNINGS PER SHARE"], "evidence_basis": "", "score_included": true}, {"title": "ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut", "summary": "ANI Pharmaceuticals ANIP reported second-quarter 2026 adjusted EPS of $2.21, beating the Zacks Consensus Estimate of $2.01. The reported figure rose 23% year over year, driven by higher sales during the quarter. Quarterly revenues totaled $266 million, up 26% from the year-ago period. The metric also beat the Zacks Consensus Estimate of $262.7 million. The quarter reflected solid execution across the portfolio, led by continued momentum for Purified Cortrophin Gel and contributions from a newly monetized intellectual property licensing arrangement. ANI's Rare Disease Business Shows Mixed Trend", "url": "https://finance.yahoo.com/healthcare/articles/anip-tops-q2-earnings-stock-170500106.html", "source_link": "https://finance.yahoo.com/healthcare/articles/anip-tops-q2-earnings-stock-170500106.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:05:00+00:00", "published_display": "10 Aug 2026 17:05", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "67f85a3485f9cdfb64f8962638f4124f4c2ec3edeb4fdf912d5be63fe2901f82", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.727, "provider_directional_mass": 0.144, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.604, "sentiment": "negative", "sentiment_pct": 39, "tone_signals": ["Guidance cut", "Beat expectations", "Missed expectations", "Improving financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.121961, "evidence_share": 13.1, "evidence_share_display": "13.1", "freshness_pct": 66.4, "age_days": 2.9, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "EARNINGS", "Earnings", "FOURTH QUARTER", "Fourth Quarter"], "evidence_basis": "", "score_included": true}, {"title": "OTLK Up More Than 300% in 3 Months: Here's What You Should Know", "summary": "Shares of Outlook Therapeutics OTLK have witnessed a significant surge over the past three months, primarily driven by growing investor optimism related to the company's sole product, Lytenava, which is approved for the treatment of patients with wet age-related macular degeneration (wet AMD). OTLK's Price Performance Shares of Outlook Therapeutics have skyrocketed 311.8% in the past three months compared with the industry's increase of 6.9%.Zacks Investment Research Image Source: Zacks Investment Research Last month, the FDA approved Lytenava for the treatment of neovascular age-related macul", "url": "https://finance.yahoo.com/healthcare/articles/otlk-more-300-3-months-152700954.html", "source_link": "https://finance.yahoo.com/healthcare/articles/otlk-more-300-3-months-152700954.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:27:00+00:00", "published_display": "10 Aug 2026 15:27", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "309a178a2358e7c2ec9d2d38e6fcc539aec61c9c4573c893f484a450ee88e629", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.773, "provider_directional_mass": 0.186, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.323, "sentiment": "positive", "sentiment_pct": 80, "tone_signals": ["Beat expectations", "Missed expectations", "Improving financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.183536, "evidence_share": 19.7, "evidence_share_display": "19.7", "freshness_pct": 65.8, "age_days": 3.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share"], "evidence_basis": "", "score_included": true}, {"title": "Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months", "summary": "Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader pipeline. The rally has been driven primarily by a series of positive regulatory developments that substantially reduced uncertainty surrounding RP1's path to commercialization. FDA Approves REPL's RP1 for Advanced Melanoma Earlier this month, the FDA granted accelerated approval to RP1 (vusolimogene oderparepvec) under the brand name Tudriqev, in combination", "url": "https://finance.yahoo.com/healthcare/articles/heres-why-replimune-stock-skyrockets-141700559.html", "source_link": "https://finance.yahoo.com/healthcare/articles/heres-why-replimune-stock-skyrockets-141700559.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:17:00+00:00", "published_display": "10 Aug 2026 14:17", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "b2f84d8c583b145125e35c48018b8ba32c55adb804feb2ec31e57b5c252094b6", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.741, "provider_directional_mass": 0.211, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.101, "sentiment": "positive", "sentiment_pct": 84, "tone_signals": ["Improving financial comparison", "Operating growth"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.239233, "evidence_share": 25.7, "evidence_share_display": "25.7", "freshness_pct": 73.8, "age_days": 3.1, "influence_label": "High", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "EARNINGS", "EARNINGS PER SHARE", "Earnings", "Earnings Per Share"], "evidence_basis": "", "score_included": true}, {"title": "Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline Progress - What's Changed", "summary": "Harmony Biosciences Holdings, Inc. recently reported second-quarter 2026 results showing net income of US$75.43 million, up from US$39.78 million a year earlier, with basic earnings per share from continuing operations rising to US$1.30 from US$0.69. Alongside these stronger earnings, the company reported progress across its neurology pipeline and clinical trials for rare neurological diseases, which could influence how investors view the balance between its current cash-generating products and longer-term development assets. We'll now examine how Harmony's sharp year-over-year earnings improv", "url": "https://finance.yahoo.com/healthcare/articles/harmony-biosciences-hrmy-9-0-231334275.html", "source_link": "https://finance.yahoo.com/healthcare/articles/harmony-biosciences-hrmy-9-0-231334275.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-07T23:13:34+00:00", "published_display": "07 Aug 2026 23:13", "provider": "eodhd", "providers": ["archive", "eodhd"], "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "3650811145d6049acefa796f0affd19e4bee6bd538ba84bb7de4fde07f9a4ea2", "target_scope": "", "durable_archive": false, "archive_provider": "", "sentiment_origin": "provider_blend", "model_confidence": 0.762, "provider_directional_mass": 0.2188, "relevance_score": 1.0, "entity_mapped": true, "sentiment_conflict": 0.313, "sentiment": "positive", "sentiment_pct": 74, "tone_signals": ["Improving financial comparison", "Operating deterioration", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.13031, "evidence_share": 14.0, "evidence_share_display": "14", "freshness_pct": 45.4, "age_days": 5.7, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "EARNINGS PER SHARE"], "evidence_basis": "", "score_included": true}, {"title": "Harmony Biosciences (HRMY) Stock Jumps On Profit Surge As Margin Pressure Lingers", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Harmony+Biosciences+%28HRMY%29+Stock+Jumps+On+Profit+Surge+As+Margin+Pressure+Lingers%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-08-05T07:45:25.721250+00:00", "published_display": "05 Aug 2026 07:45", "provider": "archive", "providers": ["archive"], "source_names": ["simplywall.st"], "source_kind": "publisher", "story_key": "552546f7a881578f10eb19f1dd197c389facb677e4e8b02174c628e7058f6054", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.485, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.667, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Margin pressure", "Operating growth", "Positive market reaction"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.03609, "evidence_share": 3.9, "evidence_share_display": "3.9", "freshness_pct": 31.5, "age_days": 8.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Harmony+Biosciences+%28HRMY%29+Stock+Looks+Below+Fair+Value+On+Earnings%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-08-02T08:09:52.665582+00:00", "published_display": "02 Aug 2026 08:09", "provider": "archive", "providers": ["archive"], "source_names": ["simplywall.st"], "source_kind": "publisher", "story_key": "0a165fccdf7b238fc1c6630387584db75708911bc888b68f18025457165c30d6", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.014985, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 20.8, "age_days": 11.3, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "HRMY Maintained by Mizuho -- Price Target Raised to $51.00", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22HRMY+Maintained+by+Mizuho+--+Price+Target+Raised+to+%2451.00%22+%22GuruFocus%22", "source_link_is_lookup": true, "source_name": "GuruFocus", "published_at": "2026-08-01T10:25:37.513979+00:00", "published_display": "01 Aug 2026 10:25", "provider": "archive", "providers": ["archive"], "source_names": ["GuruFocus"], "source_kind": "publisher", "story_key": "a70d1b715e2cb468a10294459d06f34e06c446ae4e8c0dab808922c6f5be1752", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.41, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Analyst upgrade"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006331, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 5.9, "age_days": 12.2, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Should Value Investors Buy Harmony Biosciences (HRMY) Stock?", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Should+Value+Investors+Buy+Harmony+Biosciences+%28HRMY%29+Stock%3F%22", "source_link_is_lookup": true, "source_name": "Market source", "published_at": "2026-07-31T00:16:36.107826+00:00", "published_display": "31 Jul 2026 00:16", "provider": "archive", "providers": ["archive"], "source_names": ["Market source"], "source_kind": "aggregator", "story_key": "7f370d56e74865528fbab10d688eb1fb14f52c65b177fddcdcadaa333e0d6604", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000378, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.9, "age_days": 13.7, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative?", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Did+CFO+Exit+and+Reaffirmed+2026+Guidance+Just+Shift+Harmony+Biosciences%27+%28HRMY%29+Investment+Narrative%3F%22+%22Simply+Wall+Street%22", "source_link_is_lookup": true, "source_name": "Simply Wall Street", "published_at": "2026-07-27T02:14:24.559950+00:00", "published_display": "27 Jul 2026 02:14", "provider": "archive", "providers": ["archive"], "source_names": ["Simply Wall Street"], "source_kind": "publisher", "story_key": "3e9c0b047200917c677c8952effe1e0506f56407184b4e7f3d76ce55462d8960", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.015168, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 17.6, "age_days": 17.6, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Is Harmony Biosciences' Growth Story Still Compelling in 2026", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Is+Harmony+Biosciences%27+Growth+Story+Still+Compelling+in+2026%22+%22Kavout+%7C+AI%22", "source_link_is_lookup": true, "source_name": "Kavout | AI", "published_at": "2026-07-25T06:21:53.666620+00:00", "published_display": "25 Jul 2026 06:21", "provider": "archive", "providers": ["archive"], "source_names": ["Kavout | AI"], "source_kind": "publisher", "story_key": "193e95f1ffde5e60c2490d72530a116421b23b3e32cf4441daf328bc47513ea4", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5.6e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.1, "age_days": 19.4, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "H.C. Wainwright reiterates Harmony Biosciences stock rating on demand beat", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22H.C.+Wainwright+reiterates+Harmony+Biosciences+stock+rating+on+demand+beat%22+%22Investing.com%22", "source_link_is_lookup": true, "source_name": "Investing.com", "published_at": "2026-07-21T00:38:18.298961+00:00", "published_display": "21 Jul 2026 00:38", "provider": "archive", "providers": ["archive"], "source_names": ["Investing.com"], "source_kind": "publisher", "story_key": "ac030069dfc35658c3372ee53aba1b03282cf7a88bbe3d14b321d074acbd808d", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.332, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000402, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.4, "age_days": 23.6, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Harmony Biosciences Holdings (HRMY) Is Down 8.3% After Reaffirming 2026 Guidance And CFO Transition - Has The Bull Case Changed?", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Harmony+Biosciences+Holdings+%28HRMY%29+Is+Down+8.3%25+After+Reaffirming+2026+Guidance+And+CFO+Transition+-+Has+The+Bull+Case+Changed%3F%22+%22simplywall.st%22", "source_link_is_lookup": true, "source_name": "simplywall.st", "published_at": "2026-07-18T17:19:35.386073+00:00", "published_display": "18 Jul 2026 17:19", "provider": "archive", "providers": ["archive"], "source_names": ["simplywall.st"], "source_kind": "publisher", "story_key": "2eccc6ad9aa813f7299a127a269fa600a2ad76c6045c93f1edb59eeabc33d348", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006621, "evidence_share": 0.7, "evidence_share_display": "0.7", "freshness_pct": 7.7, "age_days": 25.9, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22HRMY+Posts+Preliminary+Q2+Revenues%2C+Announces+CFO+Transition%22+%22TradingView%22", "source_link_is_lookup": true, "source_name": "TradingView", "published_at": "2026-07-18T15:49:04.642231+00:00", "published_display": "18 Jul 2026 15:49", "provider": "archive", "providers": ["archive"], "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "723400b61205a05c37c0f9f1fd3c6f8a22f84f6a773167e74ca86509970abc90", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 26.0, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}, {"title": "Zacks.com featured highlights Harmony, StoneCo, General Motors, Hewlett and Nexa", "summary": "", "url": "", "source_link": "https://www.google.com/search?tbm=nws&q=%22Zacks.com+featured+highlights+Harmony%2C+StoneCo%2C+General+Motors%2C+Hewlett+and+Nexa%22+%22Zacks%22", "source_link_is_lookup": true, "source_name": "Zacks", "published_at": "2026-07-15T12:26:09.999831+00:00", "published_display": "15 Jul 2026 12:26", "provider": "archive", "providers": ["archive"], "source_names": ["Zacks"], "source_kind": "publisher", "story_key": "37bbb9ba8c3ccd00a577cd94e2b03b894c5a05f71790adf07a04478c68d33e57", "target_scope": "", "durable_archive": true, "archive_provider": "snapshot", "sentiment_origin": "archive_headline", "model_confidence": 0.288, "provider_directional_mass": null, "relevance_score": 0.78, "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-06, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 29.1, "influence_label": "Low", "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true}], "industry": [], "sector": []}, "total_fetched": 20, "total_unique": 15, "total_relevant": 15, "total_matched": 15, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 5}, "raw_articles": 20, "unique_stories": 15, "duplicates_removed": 5, "relevant_stories": 15, "matched_archive_stories": 15, "current_evidence": 15, "direct_evidence": 15, "eodhd_articles": 5, "archive_articles": 10, "eodhd": {"configured": true, "status": "healthy", "calls_used": 405, "call_budget": 500, "budget_used_pct": 81.0, "requests_made": 81, "last_success_at": "2026-08-13T15:46:17.557916+00:00", "newest_seen_at": "2026-08-13T15:37:19+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3189, "unmapped_mentions": 1953}, "status": "healthy"}, "sentiment_summary": {"positive": 6, "negative": 1, "neutral": 8, "score": 61, "raw_score": 71, "total": 15, "evidence_count": 15, "effective_articles": 5.57, "information_mass": 0.932, "direct_story_count": 15, "direct_source_count": 9, "industry_story_count": 0, "sector_story_count": 0, "story_count": 15, "source_count": 9, "source_concentration": 0.8397, "direct_share": 100, "dispersion": 15, "confidence": 40, "evidence_status": "measured", "score_version": "evidence-v7", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-11T16:45:00+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 73, "events": [{"event": "earnings", "label": "Earnings", "weight": 3.4, "count": 6}, {"event": "general", "label": "Market update", "weight": 2.45, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.42, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.2, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 1, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 5}, "raw_articles": 20, "unique_stories": 15, "duplicates_removed": 5, "relevant_stories": 15, "matched_archive_stories": 15, "current_evidence": 15, "direct_evidence": 15, "eodhd_articles": 5, "archive_articles": 10, "eodhd": {"configured": true, "status": "healthy", "calls_used": 405, "call_budget": 500, "budget_used_pct": 81.0, "requests_made": 81, "last_success_at": "2026-08-13T15:46:17.557916+00:00", "newest_seen_at": "2026-08-13T15:37:19+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3189, "unmapped_mentions": 1953}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 38.41, "latest_week": "2026-08-07", "one_week_move": 9.0, "four_week_move": 4.3, "twelve_week_move": 27.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.87825, "market_dynamics_buy_signal": false, "relative_strength": 1.407682, "fair_value_gap": 16.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 42.1327, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.0% over one week, +4.3% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 57, "badges": ["Sentiment confirms active trend"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": [], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "GuruFocus", "count": 1}, {"label": "Market source", "count": 1}, {"label": "Simply Wall Street", "count": 1}, {"label": "Kavout | AI", "count": 1}, {"label": "Investing.com", "count": 1}, {"label": "TradingView", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 15}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 6}, {"label": "Market update", "count": 4}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "61/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "40/100", "tone": "neutral", "text": "5.57 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "73/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "15", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "15/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+9.0% over one week, +4.3% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge"}], "updated_at": "2026-08-13T15:52:39.318255+00:00", "detail_intelligence": {"headline": "Constructive news tone", "summary": "The score uses 15 current company stories from 9 publishers.", "status": "measured", "metrics": [{"label": "News score", "value": 61, "display": "61", "tone": "positive", "note": "Constructive news tone"}, {"label": "Confidence", "value": 40, "display": "40", "tone": "neutral", "note": "building confidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "15 company stories"}, {"label": "Story agreement", "value": 85, "display": "85", "tone": "positive", "note": "15/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 19, "note": "0.932 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "9 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 55, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 85, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 16, "note": "less reliance on one publisher"}], "freshness": 55, "source_independence": 16, "timeline": [{"date": "2026-07-15", "label": "15 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-07-16", "label": "16 Jul", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-17", "label": "17 Jul", "count": 0, "score": null, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-18", "label": "18 Jul", "count": 2, "score": 50, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 34.7, "volume_y": 231.3}, {"date": "2026-07-19", "label": "19 Jul", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-20", "label": "20 Jul", "count": 0, "score": null, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-21", "label": "21 Jul", "count": 1, "score": 57, "tone": "neutral", "x": 231.5, "y": 122.3, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-07-22", "label": "22 Jul", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-23", "label": "23 Jul", "count": 0, "score": null, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-01", "label": "01 Aug", "count": 1, "score": 69, "tone": "positive", "x": 579.0, "y": 100.4, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-02", "label": "02 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 1, "score": 55, "tone": "neutral", "x": 705.3, "y": 125.9, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 1, "score": 74, "tone": "positive", "x": 768.5, "y": 91.3, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 3, "score": 73, "tone": "positive", "x": 863.2, "y": 93.1, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 1, "score": 72, "tone": "positive", "x": 894.8, "y": 95.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-12", "label": "12 Aug", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "42.0,135.0 136.8,135.0 231.5,122.3 357.9,135.0 421.0,135.0 547.4,135.0 579.0,100.4 610.6,135.0 705.3,125.9 768.5,91.3 863.2,93.1 894.8,95.0", "timeline_has_signal": true, "timeline_start": "15 Jul", "timeline_mid": "30 Jul", "timeline_end": "13 Aug", "momentum": {"label": "Tentative cooling", "tone": "neutral", "recent_score": 59, "prior_score": 80, "delta": -21, "recent_count": 2, "prior_count": 3, "volume_delta": -1, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 2, "share": 13}, {"label": "4 to 7 days", "count": 3, "share": 20}, {"label": "8 to 14 days", "count": 4, "share": 27}, {"label": "15 to 21 days", "count": 2, "share": 13}, {"label": "22 to 30 days", "count": 4, "share": 27}], "source_profile": [{"label": "finance.yahoo.com", "count": 5, "share": 33, "score": 73, "tone": "positive"}, {"label": "simplywall.st", "count": 3, "share": 20, "score": 53, "tone": "neutral"}, {"label": "GuruFocus", "count": 1, "share": 7, "score": 69, "tone": "positive"}, {"label": "Investing.com", "count": 1, "share": 7, "score": 57, "tone": "neutral"}, {"label": "Market source", "count": 1, "share": 7, "score": 50, "tone": "neutral"}, {"label": "Simply Wall Street", "count": 1, "share": 7, "score": 50, "tone": "neutral"}, {"label": "Kavout | AI", "count": 1, "share": 7, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Earnings", "count": 6, "share": 40, "score": 67, "tone": "positive"}, {"label": "Market update", "count": 4, "share": 27, "score": 50, "tone": "neutral"}, {"label": "Analyst action", "count": 2, "share": 13, "score": 68, "tone": "positive"}, {"label": "Guidance", "count": 2, "share": 13, "score": 50, "tone": "neutral"}, {"label": "Regulatory and legal", "count": 1, "share": 7, "score": 84, "tone": "positive"}], "topics": [{"label": "EARNINGS", "count": 5, "share": 33}, {"label": "Biotech", "count": 5, "share": 33}, {"label": "BIOTECH", "count": 5, "share": 33}, {"label": "EARNINGS PER SHARE", "count": 4, "share": 27}, {"label": "Earnings", "count": 3, "share": 20}, {"label": "Earnings Per Share", "count": 2, "share": 13}, {"label": "Clinical Trials", "count": 2, "share": 13}, {"label": "CLINICAL-TRIALS", "count": 2, "share": 13}, {"label": "Fourth Quarter", "count": 1, "share": 7}, {"label": "FOURTH QUARTER", "count": 1, "share": 7}], "supporting": [{"label": "Direct evidence", "text": "15 current stories are mapped specifically to HRMY."}, {"label": "Source breadth", "text": "The read spans 9 publishers rather than depending on one outlet."}, {"label": "Story agreement", "text": "The current stories agree at 85/100."}, {"label": "Price response", "text": "Constructive news tone is being confirmed by positive weekly price action."}], "tempering": [], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge", "summary": "BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over year to $243.7 million, beating the Zacks Consensus Estimate of $222.6 million. This growth was primarily driven by its sole marketed drug, Attruby. Year to date, BridgeBio's shares have gained 11% compared with the industry's 7% growth.Zacks Investment Research Image Source: Zacks Investment Research BBIO's Attruby Sales Drive the Top Line A", "url": "https://finance.yahoo.com/healthcare/articles/bridgebio-q2-earnings-miss-revenues-164500986.html", "source_link": "https://finance.yahoo.com/healthcare/articles/bridgebio-q2-earnings-miss-revenues-164500986.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:45:00+00:00", "published_display": "11 Aug 2026 16:45", "source_kind": "aggregator", "sentiment": "positive", "sentiment_pct": 72, "tone_signals": ["Beat expectations", "Improving financial comparison", "Deteriorating financial comparison", "Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.176759, "evidence_share": 19.0, "evidence_share_display": "19", "freshness_pct": 76.2, "age_days": 2.0, "influence_label": "Medium", "duplicate_count": 2, "topics": ["BIOTECH", "Biotech", "CLINICAL-TRIALS", "Clinical Trials", "EARNINGS", "EARNINGS PER SHARE"], "evidence_basis": "", "score_included": true}, "article_count": 15, "updated_at": "2026-08-13T15:52:39.318255+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 85.8, "label": "13 Feb 2026", "close": 36.01, "index": 100.0}, {"x": 78.4, "y": 171.4, "label": "20 Feb 2026", "close": 29.16, "index": 81.0}, {"x": 114.9, "y": 179.2, "label": "27 Feb 2026", "close": 28.54, "index": 79.3}, {"x": 151.3, "y": 181.8, "label": "06 Mar 2026", "close": 28.33, "index": 78.7}, {"x": 187.7, "y": 190.8, "label": "13 Mar 2026", "close": 27.61, "index": 76.7}, {"x": 224.2, "y": 189.4, "label": "20 Mar 2026", "close": 27.72, "index": 77.0}, {"x": 260.6, "y": 204.2, "label": "27 Mar 2026", "close": 26.54, "index": 73.7}, {"x": 297.0, "y": 189.2, "label": "03 Apr 2026", "close": 27.74, "index": 77.0}, {"x": 333.5, "y": 174.8, "label": "10 Apr 2026", "close": 28.89, "index": 80.2}, {"x": 369.9, "y": 161.1, "label": "17 Apr 2026", "close": 29.99, "index": 83.3}, {"x": 406.3, "y": 150.9, "label": "24 Apr 2026", "close": 30.8, "index": 85.5}, {"x": 442.8, "y": 138.1, "label": "01 May 2026", "close": 31.83, "index": 88.4}, {"x": 479.2, "y": 148.6, "label": "08 May 2026", "close": 30.99, "index": 86.1}, {"x": 515.6, "y": 159.8, "label": "15 May 2026", "close": 30.09, "index": 83.6}, {"x": 552.0, "y": 159.1, "label": "22 May 2026", "close": 30.15, "index": 83.7}, {"x": 588.5, "y": 141.1, "label": "29 May 2026", "close": 31.59, "index": 87.7}, {"x": 624.9, "y": 133.4, "label": "05 Jun 2026", "close": 32.2, "index": 89.4}, {"x": 661.3, "y": 105.2, "label": "12 Jun 2026", "close": 34.46, "index": 95.7}, {"x": 697.8, "y": 119.9, "label": "19 Jun 2026", "close": 33.28, "index": 92.4}, {"x": 734.2, "y": 92.6, "label": "26 Jun 2026", "close": 35.47, "index": 98.5}, {"x": 770.6, "y": 70.2, "label": "03 Jul 2026", "close": 37.26, "index": 103.5}, {"x": 807.1, "y": 75.4, "label": "10 Jul 2026", "close": 36.84, "index": 102.3}, {"x": 843.5, "y": 113.8, "label": "17 Jul 2026", "close": 33.77, "index": 93.8}, {"x": 879.9, "y": 94.4, "label": "24 Jul 2026", "close": 35.32, "index": 98.1}, {"x": 916.4, "y": 95.4, "label": "31 Jul 2026", "close": 35.24, "index": 97.9}, {"x": 952.8, "y": 55.8, "label": "07 Aug 2026", "close": 38.41, "index": 106.7}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 21, "stories": 2, "close": 35.47, "price_change": 6.6, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 25, "stories": 8, "close": 37.26, "price_change": 5.0, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 18, "stories": 9, "close": 36.84, "price_change": -1.1, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 22, "stories": 12, "close": 33.77, "price_change": -8.3, "x": 848.7, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 52, "confidence": 22, "stories": 13, "close": 35.32, "price_change": 4.6, "x": 885.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 24, "stories": 12, "close": 35.24, "price_change": -0.2, "x": 921.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 55, "tone": "neutral", "raw_score": 65, "confidence": 33, "stories": 13, "close": 38.41, "price_change": 9.0, "x": 958.0, "y": 120.8, "show_label": true, "label_y": 110.8}], "price_path": "42.0,85.8 78.4,171.4 114.9,179.2 151.3,181.8 187.7,190.8 224.2,189.4 260.6,204.2 297.0,189.2 333.5,174.8 369.9,161.1 406.3,150.9 442.8,138.1 479.2,148.6 515.6,159.8 552.0,159.1 588.5,141.1 624.9,133.4 661.3,105.2 697.8,119.9 734.2,92.6 770.6,70.2 807.1,75.4 843.5,113.8 879.9,94.4 916.4,95.4 952.8,55.8", "sentiment_path": "739.4,130.0 775.8,130.0 812.3,130.0 848.7,130.0 885.1,130.0 921.6,130.0 958.0,120.8", "score_version": "evidence-v7", "price_change": 6.7, "sentiment_change": 5, "recent_pairs": [{"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 55, "tone": "neutral", "raw_score": 65, "confidence": 33, "stories": 13, "close": 38.41, "price_change": 9.0, "x": 958.0, "y": 120.8, "show_label": true, "label_y": 110.8}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 24, "stories": 12, "close": 35.24, "price_change": -0.2, "x": 921.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 52, "confidence": 22, "stories": 13, "close": 35.32, "price_change": 4.6, "x": 885.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 22, "stories": 12, "close": 33.77, "price_change": -8.3, "x": 848.7, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 18, "stories": 9, "close": 36.84, "price_change": -1.1, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 25, "stories": 8, "close": 37.26, "price_change": 5.0, "x": 775.8, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 21, "stories": 2, "close": 35.47, "price_change": 6.6, "x": 739.4, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 38.41, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug", "live_score_version": "evidence-v7", "comparable_to_live": true}, "sentiment_history": [{"label": "20 Jun 23:59", "short_label": "20 Jun", "collected_at": "2026-06-20T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 4, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "28 Jun 23:59", "short_label": "28 Jun", "collected_at": "2026-06-28T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "01 Jul 23:59", "short_label": "01 Jul", "collected_at": "2026-07-01T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "06 Jul 23:59", "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Jul 23:59", "short_label": "11 Jul", "collected_at": "2026-07-11T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 14, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 14, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "25 Jul 23:59", "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 14, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": -1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 4, "article_change": 0, "tone": "neutral", "height": 4, "articles": 12, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 12, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 12, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 4, "score_change_display": "+4", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 10, "articles": 13, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 4, "score_change_display": "+4", "confidence_change": 9, "article_change": 2, "tone": "positive", "height": 18, "articles": 15, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "positive", "height": 20, "articles": 16, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "13 Aug 15:52", "short_label": "13 Aug", "collected_at": "2026-08-13T15:52:39.325484+00:00", "score": 60, "delta": 10, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "positive", "height": 20, "articles": 15, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v7", "live_version": "evidence-v7", "comparable_to_live": true, "reconstructed": true, "observations": 23, "span_label": "54 days", "first_score": 50, "latest_score": 60, "net_change": 10, "net_change_display": "+10", "direction": "Strengthening", "high_score": 60, "low_score": 50, "latest_confidence": 39, "confidence_change": 14, "latest_articles": 15, "article_change": 14, "latest_label": "13 Aug 15:52", "latest_evidence_label": "Measured", "chart_rows": [{"label": "20 Jun 23:59", "short_label": "20 Jun", "collected_at": "2026-06-20T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 42.0, "y": 135.0}, {"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 83.6, "y": 135.0}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 4, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 125.3, "y": 135.0}, {"label": "28 Jun 23:59", "short_label": "28 Jun", "collected_at": "2026-06-28T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 166.9, "y": 135.0}, {"label": "01 Jul 23:59", "short_label": "01 Jul", "collected_at": "2026-07-01T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 208.5, "y": 135.0}, {"label": "02 Jul 23:59", "short_label": "02 Jul", "collected_at": "2026-07-02T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 250.2, "y": 135.0}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 291.8, "y": 135.0}, {"label": "06 Jul 23:59", "short_label": "06 Jul", "collected_at": "2026-07-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 333.5, "y": 135.0}, {"label": "11 Jul 23:59", "short_label": "11 Jul", "collected_at": "2026-07-11T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 375.1, "y": 135.0}, {"label": "14 Jul 23:59", "short_label": "14 Jul", "collected_at": "2026-07-14T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 416.7, "y": 135.0}, {"label": "15 Jul 23:59", "short_label": "15 Jul", "collected_at": "2026-07-15T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 458.4, "y": 135.0}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 14, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 500.0, "y": 135.0}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 14, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 541.6, "y": 133.2}, {"label": "25 Jul 23:59", "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 14, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 583.3, "y": 135.0}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": -1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 624.9, "y": 135.0}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 666.5, "y": 135.0}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 4, "article_change": 0, "tone": "neutral", "height": 4, "articles": 12, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 708.2, "y": 131.4}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 12, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 749.8, "y": 131.4}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 12, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 791.5, "y": 133.2}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 4, "score_change_display": "+4", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 10, "articles": 13, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true, "x": 833.1, "y": 125.9}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 4, "score_change_display": "+4", "confidence_change": 9, "article_change": 2, "tone": "positive", "height": 18, "articles": 15, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 874.7, "y": 118.6}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "positive", "height": 20, "articles": 16, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 916.4, "y": 116.8}, {"label": "13 Aug 15:52", "short_label": "13 Aug", "collected_at": "2026-08-13T15:52:39.325484+00:00", "score": 60, "delta": 10, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "positive", "height": 20, "articles": 15, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true, "x": 958.0, "y": 116.8}], "chart_points": "42.0,135.0 83.6,135.0 125.3,135.0 166.9,135.0 208.5,135.0 250.2,135.0 291.8,135.0 333.5,135.0 375.1,135.0 416.7,135.0 458.4,135.0 500.0,135.0 541.6,133.2 583.3,135.0 624.9,135.0 666.5,135.0 708.2,131.4 749.8,131.4 791.5,133.2 833.1,125.9 874.7,118.6 916.4,116.8 958.0,116.8", "changes": [{"label": "13 Aug 15:52", "short_label": "13 Aug", "collected_at": "2026-08-13T15:52:39.325484+00:00", "score": 60, "delta": 10, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "positive", "height": 20, "articles": 15, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "positive", "height": 20, "articles": 16, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 4, "score_change_display": "+4", "confidence_change": 9, "article_change": 2, "tone": "positive", "height": 18, "articles": 15, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v7", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 4, "score_change_display": "+4", "confidence_change": 4, "article_change": 1, "tone": "neutral", "height": 10, "articles": 13, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 12, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 12, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 4, "article_change": 0, "tone": "neutral", "height": 4, "articles": 12, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v7", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}